Project Grant DP2GM149752
- The National Institute of General Medical Sciences (NIGMS) awarded Epicypher, Inc. a $1,264,176 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to develop a novel manufacturing method for asymmetric designer nucleosomes (A-DNucs). The goal is to advance the study of the "histone code" - the complex signaling mechanisms by which post-translational modifications on histones regulate chromatin function and gene expression. The technical innovation...
- This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) supports research to visualize the mechanisms at the intersection of chromatin, transcription, and epigenetics. The $1,525,500 award to Harvard Medical School aims to develop a combinatorial biochemical and structural approach called "Visual Biochemistry" that uses a fully reconstituted chromatin transcription system and time-resolved single-particle...
- This National Science Foundation (NSF) Division of Chemical, Bioengineering, Environmental, and Transport Systems Project Grant of $500,000 awarded to Beth Israel Deaconess Medical Center, Inc. (Bidmc) aims to develop a novel, label-free method for dynamically sensing chromatin packing and structure in live cells. The 3-year project leverages the principles of fractal sensing and coherent confocal light absorption and scattering spectroscopic microscopy to create a 3D dynamic map of chromatin...
- This Project Grant award from the National Science Foundation's (NSF) Mathematical and Physical Sciences (CFDA 47.049) program provides $200,000 in funding to The Trustees of the University of Pennsylvania to conduct collaborative research that aims to understand genomic organization in the cell nucleus. The research team will employ an integrated approach leveraging biophysical modeling, super-resolution imaging, and machine learning to develop predictive models of how chromatin structure and...
- This Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $1,507,500.00 to Yale University to conduct research on the regulatory mechanisms by which the genome encodes non-genetic heterogeneity in cell systems. The project aims to identify transcription factor pairs that drive transcriptional heterogeneity, determine heritable memory loci capable of transmitting non-genetic heterogeneity across...
- This two-year, $1,204,512 National Science Foundation project grant supports research into the robustness and adaptability of the dynamic epigenome through a multiscale approach. Funded under the Biological Sciences program (CFDA 47.074), the award to Brandeis University involves investigating the fundamental rules that guide adaptive epigenetic changes in cells without alterations to the genetic blueprint. The research utilizes high-resolution imaging, microfluidics, and automated culture...
- This $1,737,000 Project Grant awarded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports the development of innovative single-cell genomics technologies for joint analysis of regulatory dynamics and transcriptional states. Key objectives include: Developing multiomics tools to measure rates of epigenomic changes (DNA methylation, demethylation, oxidative damage, DNA repair) and relate these to...
- This Project Grant award of $374,999.00 from the National Science Foundation (NSF) Biological Sciences program (CFDA 47.074) supports collaborative research by the University of California, San Diego (UCSD) to investigate the mechanisms that enable analog information storage in the chromatin state of cells. The project aims to determine how the positive feedback loop between DNA methylation and histone H3 lysine 9 trimethylation dictates whether gene expression memory is binary or analog....
- This four-year, $1.388 million project grant from the National Science Foundation's Mathematical and Physical Sciences program (CFDA 47.049) supports collaborative research between New York University and other organizations to discover the principles of active self-organization in the differentiating genome. The research will integrate state-of-the-art live cell experiments with multiscale mathematical and computational models of chromatin dynamics in the cell nucleus. Experiments will...
- The federal Project Grant award titled "Time-Lapse Epigenome Profiling in Support of Next Generation Cellular Reprogramming" was provided by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310). The $1,399,500 award to the Washington University will fund a 3-year research project to observe epigenetic factors that influence the efficiency of cellular reprogramming, a process that can convert non-target cell types like fibroblasts into...
HARNESSING THE CHROMATIN CONFORMATIONAL CODE FOR EPIGENETIC REGULATION - PROJECT SUMMARY EUKARYOTIC DNA IS WRAPPED AROUND NUCLEOSOMES, WHICH FORM CHAINS OF CHROMATIN THAT ARE FURTHER FOLDED INTO THREE-DIMENSIONAL ASSEMBLIES. THE ARCHITECTURE OF THESE ASSEMBLIES REGULATES MANY NUCLEAR FUNCTIONS, INCLUDING GENOME 3D FOLDING AND TRANSCRIPTION, AND ULTIMATELY DICTATES CELLULAR IDENTITY. NUCLEOSOMES ARE A WELL-KNOWN HUB OF CHROMATIN REGULATION, MOST OF WHICH IS THOUGHT TO OCCUR VIA A VARIETY OF POST-TRANSLATIONAL MODIFICATIONS ON THE PROTRUDING FLEXIBLE TAILS OF HISTONES. BASED ON THE ASSUMPTION THAT MOST REGULATION OF CHROMATIN'S STRUCTURE AND INTERACTIONS WITH OTHER FACTORS OCCURS AT THESE HISTONE TAILS, THE GLOBULAR CORE OF NUCLEOSOMES HAS BEEN CONSIDERED RIGID AND MINIMALLY REGULATORY. EXCITINGLY, MY RECENT WORK HAS REVEALED A NEW INSIGHT: THAT THE NUCLEOSOME CORE IS MALLEABLE AND THAT THIS PLASTICITY REGULATES CHROMATIN FOLDING AND GENE REPRESSION. I THEREFORE PROPOSE THAT THE GLOBULAR, MALLEABLE CORE OF NUCLEOSOMES IS A HUB FOR GENETIC AND EPIGENETIC REGULATION AS WELL AS A POTENTIAL NOVEL THERAPEUTIC TARGET. TO TEST THIS PROVOCATIVE HYPOTHESIS THAT CHALLENGES THE TEXTBOOK PARADIGM OF CHROMATIN REGULATION, NOVEL TOOLS CAPABLE OF PROBING BOTH IN VITRO AND IN VIVO ATOMIC-SCALE DYNAMICS OF LARGE MACROMOLECULAR ASSEMBLIES SUCH AS CHROMATIN MUST BE DEVELOPED. MY LAB WILL CLOSE THIS GAP BY DEVELOPING CONFORMATION-SPECIFIC NANOBODIES (NANONUCS) THAT ACT AS SENSORS OF DISTINCT NUCLEOSOME CONFORMATIONS. NANONUCS WILL BE DISCOVERED FROM A SYNTHETIC LIBRARY CONTAINING >2 X 109 DISTINCT NANOBODIES. WE WILL EMPLOY NANONUCS TO GAIN STRUCTURAL AND BIOPHYSICAL INSIGHTS INTO NUCLEOSOME CONFORMATIONAL DYNAMICS AND TO PROBE AND PERTURB THE NUCLEOSOME CONFORMATIONAL CODE IN CELLS. SPECIFICALLY, WE WILL: (I) OBTAIN ATOMIC UNDERSTANDING OF NUCLEOSOME ALTERNATIVE STATES BY COMBINING NMR, HDX-MS, AND CRYO-EM; (II) IDENTIFY CHROMATIN FACTORS THAT SENSE AND LEVERAGE NUCLEOSOME PLASTICITY; (III) SEARCH FOR NUCLEOSOME CONFORMATIONS THAT ARE BIOLOGICAL OR PATHOLOGICAL BIOMARKERS; AND (IV) DEVELOP A NOVEL STRATEGY TO MANIPULATE NUCLEOSOME SHAPES AND CHROMATIN STATES IN CELLS. BY CARRYING OUT THIS HIGHLY AMBITIOUS, INTEGRATED, AND MULTIDISCIPLINARY RESEARCH PROGRAM, MY LAB WILL UNVEIL THE MOLECULAR MECHANISMS AND THERAPEUTICAL POTENTIAL OF THE NUCLEOSOME CONFORMATIONAL CODE. I ANTICIPATE THAT THESE HIGH-RISK, HIGH-REWARD INVESTIGATIONS WILL REVEAL NEW FUNDAMENTAL PRINCIPLES OF GENOME REGULATION THAT SHIFT THE LONG-STANDING PARADIGM OF RIGID HISTONE UNITS AND THAT WILL BROADLY IMPACT BIOMEDICAL SCIENCE OVER THE SHORT AND LONG TERMS. EXPLORING THE STRUCTURAL FLEXIBILITY OF NUCLEOSOMES REPRESENTS AN OPPORTUNITY TO IDENTIFY NOVEL THERAPEUTIC BIOMARKERS AND DRUGS FOR DISEASES LINKED TO EPIGENETICS DEFECTS, SUCH AS CANCER. ULTIMATELY, WITH CRITICAL SUPPORT FROM THE NIH DIRECTOR'S NEW INNOVATOR PROGRAM, OUR STUDIES WILL ENRICH OUR KNOWLEDGE OF THE FUNCTION AND PHYSIOLOGY OF CHROMATIN WITH ATOMIC-SCALE BIOPHYSICAL INSIGHTS INTO THE CHROMATIN ARCHITECTURE ITSELF.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $924.0k | 8/15/25 | ||
| Not listed | $1.4m | 8/30/22 | ||
| Not listed | $1.4m | 8/30/22 |